Chronic fatigue syndrome Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Chronic fatigue syndrome Market is segmented By Type (Immune Enhancer & Antivirals, Sleep Enhancing, CNS Stimulants, Others), By End-User (Hospitals, Clinics, Research Institutes), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Chronic Fatigue Syndrome Market Overview

The global chronic fatigue syndrome market is estimated to reach a high CAGR during the forecast period 2024-2031.

Chronic fatigue syndrome is also called myalgic encephalomyelitis, a chronic disorder associated with long-term fatigue and tiredness in patients. Any condition cannot define these symptoms.

Chronic Fatigue Syndrome Market Scope

To Know More Insights - Download Sample

Chronic Fatigue Syndrome Market Dynamics

 Increasing techniques to find the symptoms of chronic fatigue syndrome (CFS) is expected to drive the market's growth.

According to the BMJ Journal, on February 1, 2021. They have explored the relationship between chronic fatigue syndrome (CFS) and fibromyalgia (FM) using a quasi-experimental design. Invariance was confirmed except for the American CDC Symptom Inventory, Fibromyalgia Impact Questionnaire and Hospital Anxiety and Depression Scale (p<0.05) based on five questions. Consequently, it was incorrect to conclude differences. Therefore, the Syndrome Model was created.  Consequently, it is combined with these three questionnaires, increasing the data points, to create this new measurable model. Results confirmed no significant differences between groups (p=0.07 (p<0.05)). Thus, participants responded similarly to the questionnaire, confirming the same symptom experience. It is important to consider this in context with differing criteria and management guidelines, as this may influence diagnosis and patient management trajectory. With the biomedical cause currently unclear, the symptom experience and the impact on quality of life are important. These findings are meaningful for patients, clinicians and policy development and support the requirement for future research. Therefore, from the above statements, it is expected to drive the market's growth in the forecast period.

The increasing prevalence of chronic fatigue syndrome (CFS) is expected to drive the market's growth.

According to the Medicina, in 2021. Prevalence rates have been estimated as between 0.1 and 0.7% and the incidence rate as 0.015 new cases/1000-year. Moreover, it could represent between 1 million and over 5 million people, probably around 3 million, in the European continent living with chronic fatigue syndrome (CFS). However, there are no European-wide estimates of disease burden. Many people will have chronic fatigue for other reasons, and many of them are significantly hindered. At least 2/3 of the cases are in women, with young people in their most productive phases of life being preferentially affected. However, ME/CFS has been reported in all age groups. The quality of life of those with ME/CFS is on average lower than with other chronic or disabling diseases, such as multiple sclerosis, cancer, rheumatoid arthritis, depression, diabetes, epilepsy, or cystic fibrosis. Thus, the above factors are expected to drive the growth of the market in the forecast period.

The Economic Impacts of Chronic Fatigue Syndrome in an Australian Cohort are expected to hamper the market's growth.

According to the research article, on 21 August 2020. A cost of illness study is conducted to estimate Australian cost data for individuals with a ME/CFS diagnosis as determined by the Canadian Consensus Criteria (CCC), International Consensus Criteria (ICC), and the 1994 CDC Criteria (Fukuda). Moreover, Survey participants identified from a research registry database provided a self-report of expenditure associated with ME/CFS-related healthcare across a 1-month timeframe between 2017 and 2019. Additionally, the mean annual cost of healthcare-related expenditure and associated income loss among survey participants meeting diagnostic criteria for ME/CFS is estimated at $14.5 billion. For direct OOP and Government health care expenditure, high average costs were related to medical practitioner attendance, diagnostics, natural medicines, and device expenditure, with an average attendance of 10.6 referred attendances per annum and 12.1 GP visits per annum related specifically to managing ME/CFS. Thus, from the above statements, the market is expected to get hampered in the forecast period.

Chronic Fatigue Syndrome Market Industry Analysis

COVID-19 Impact Analysis

The COVID-19 pandemic has caused overwhelming challenges in healthcare worldwide. According to the study conducted by the Gavi on 19 June 2020, which is done in Hong Kong, 40% of people recovering from SARS still had chronic fatigue symptoms 3.5 years after being diagnosed. Viral infections such as SARS and Epstein-Barr virus trigger chronic fatigue syndrome that can last for months or years. Moreover, COVID-19 has complicated the treatment of chronic fatigue symptoms in patients. Research into the new disease is benefiting from insights gained over years of chronic fatigue syndrome research.

Further researches are needed to recognize the advanced planning and rapid responses to reduce the impact of the pandemic as stakeholders are increasingly searching for newer approaches towards diagnosing and curing patients affected by the COVID-19.

Chronic Fatigue Syndrome Market Segment Analysis

Sleep Enhancing segment is expected to hold the largest market share in this market segment.

The sleep-enhancing segment held the largest market share in 2020. The segment's growth is attributed to increasing sleep disorders, and increasing genetic susceptibility in patients with CFS is expected to boost the market in the forecast period. For instance, according to the National Center for Biotechnology Information, on June 11, 2021. There has been increasing evidence supports the role of genetic susceptibility in patients with CFS. Family history studies of chronic fatigue syndrome have shown significantly higher family members rates of the patient reporting CFS or similar fatigue-like symptoms. Studies from the twin registry also have shown increased familial and genetic predisposition of the condition. A study has reported variability in the expression of specific genes in patients with CFS, particularly after exercise, which affects the metabolism and immune responses. At the same time, another study has shown a linkage between CFS, specific genetic mutations, and viral infections.

Moreover, non-restorative sleep despite sufficient or extended total sleep time is one of the major clinical diagnostic criteria; however, the underlying cause of this symptom is unknown. Additionally, polysomnographic and other objective measures of sleep have observed few variations in sleep parameters between CFS/ME patients and healthy controls, although some discrepancies exist.

This lack of significant objective differences differs from the common subjective complaints of disturbed and unrefreshed sleep by CFS/ME patients. The emergence of new, more sensitive techniques that examine the microstructure of sleep shows promise for detecting differences in sleep between patients and healthy individuals. There is preliminary evidence that alterations in sleep stage transitions and sleep instability, and other physiological mechanisms, such as heart rate variability and altered cortisol profiles, may be evident. Thus, from the above factors, the segment is expected to hold the largest market segment.

Chronic Fatigue Syndrome Market Geographical Share

North America region holds the largest market share in the global Chronic fatigue syndrome market.

North America dominated the market and accounted for the largest revenue share in 2020. The region's growth is benefited due to changing lifestyles, increasing healthcare expenditure, and increasing cases of chronic fatigue syndrome in adolescents are expected to boost the market in the forecast period. For instance, according to the Journal of Cambridge University published on 1 April 2020. Chronic fatigue syndrome (CFS) has a major impact on functioning. However, no validated measures of functioning for this population exist. They aimed o establish the psychometric properties of the 5-item School and Social Adjustment Scale (SSAS) and the 10-item Physical Functioning Subscale of the SF-36 in adolescents with CFS.

Moreover, measures were completed by adolescents with CFS (n = 121). Thus, both measures are reliable and valid and provide brief measures for assessing these important outcomes. The Physical Functioning Subscale can be used as two subscales in adolescents with CFS. Additionally, the rise in the availability of funds for research, a huge patient population, a well-developed healthcare sector and government support for research & development in this region hold the largest market share.

Chronic Fatigue Syndrome Market Companies and Competitive Landscape

The chronic fatigue syndrome market is vast with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Hemispherx Biopharma, Inc., Torrent Pharmaceuticals Ltd., Fortis Healthcare, F. Hoffmann-La Roche Ltd, K-PAX Pharmaceuticals, Inc., Dr Batra's, London School of Hygiene L, Tropical Medicine – CureME. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the chronic fatigue syndrome market globally.

Chronic fatigue syndrome Market Key Companies to Watch

Torrent Pharmaceuticals Limited:

Overview:

­Torrent Pharmaceuticals Ltd is an Indian multinational pharmaceutical company owned by Torrent Group, headquartered in Ahmedabad, India. It was promoted by U. N. Mehta, initially as Trinity Laboratories Ltd, and was later renamed Torrent Pharmaceuticals Ltd. Moreover, the company is operated in more than 40 countries with over 2000 product registrations globally. It is active in the therapeutic areas of cardiovascular (CV), central nervous system (CNS), gastrointestinal, diabetology, anti-infective and pain management segments. It has also forayed into the therapeutic segments of nephrology and oncology while also strengthening its focus on gynecology and pediatric segments.

Product Portfolio:

Torrent Pharmaceuticals Ltd. has continuously set new standards for continuous manufacturing of Alcohol Deaddiction, Anti-Depressant, Anti-Epileptic drugs, Stimulants and other medications.

The global chronic fatigue syndrome market report would provide an access to an approx.41 market data table, 39 figures and 200pages.